Onsdag 2 April | 11:43:18 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-28 08:00 Bokslutskommuniké 2025
2025-11-11 08:00 Kvartalsrapport 2025-Q3
2025-08-12 08:00 Kvartalsrapport 2025-Q2
2025-06-30 N/A X-dag ordinarie utdelning PTRK 0.00 SEK
2025-06-27 N/A Årsstämma
2025-05-13 08:00 Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-11-12 - Kvartalsrapport 2024-Q3
2024-08-13 - Kvartalsrapport 2024-Q2
2024-05-14 - Kvartalsrapport 2024-Q1
2024-05-06 - X-dag ordinarie utdelning PTRK 0.00 SEK
2024-05-03 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-15 - Kvartalsrapport 2023-Q2
2023-05-04 - X-dag ordinarie utdelning PTRK 0.00 SEK
2023-05-03 - Årsstämma
2023-05-02 - Kvartalsrapport 2023-Q1
2023-02-28 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-26 - Kvartalsrapport 2022-Q1
2022-05-04 - X-dag ordinarie utdelning PTRK 0.00 SEK
2022-05-03 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-07-28 - Kvartalsrapport 2021-Q2

Beskrivning

LandStorbritannien
ListaFirst North Stockholm
SektorInformationsteknik
IndustriProgramvara
Physitrack är verksamt inom hälsovårdssektorn. Bolaget är specialiserat inom sjukgymnastik. Produktportföljen inkluderar digitala vårderbjudanden till företag via SaaS-lösningar. Utöver huvudverksamheten erbjuds även personlig service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa och Nordamerika. Physitrack grundades 2012 och har sitt huvudkontor i London.
2025-02-26 20:30:00

London, 26 February 2025 – Physitrack plc has today announced a restatement of its 2023 financial accounts and unaudited Q1-Q3 2024 quarterly figures following the identification of overstatements in accrued revenue from prior periods in its subsidiary Champion Health Plus.

The adjustment stems from an over-accrual of revenue identified during 2024 financial reconciliations, resulting in an overstatement in 2023 of £374,165 (€430,295) or 2% of 2023 revenue, and 2022 of £77,911 (€91,371). The correction relates to the historic physiotherapy appointments revenue stream in the business and the error arose due to issues with data extraction from the appointment booking system, which have been addressed going forward.

The restatement of the 2023 revenue results in a provision of £99,718 (€120,645) built up in Q1-Q3 2024 no longer being required. Profit figures for Q1-Q3 2024 will therefore be increased, see the below tables for corrected figures.

A Spotlight interview with CEO & co-founder Henrik Molin on the subject can be found here:
https://vimeo.com/1053188072/bf4cddce87

Key Adjustments:

2023 Adjustment Euro





Q12023Q22023Q32023Q42023FY2023
Revenue




As previously reported3,734,7193,750,9723,851,2303,839,66115,176,582
Adjustment(72,183)(96,606)(133,465)(128,041)(430,295)
Restated3,662,5363,654,3663,717,7653,711,62014,746,287






Profit after tax




As previously reported(65,636)(251,656)(240,160)3,762,2783,204,826
Adjustment(72,183)(96,606)(133,465)(82,054)(384,308)
Restated(137,819)(348,262)(373,625)3,680,2242,820,518






Adjusted EBITDA




As previously reported922,090953,6561,051,111979,9753,906,832
Adjustment(72,183)(96,606)(133,465)(128,041)(430,295)
Restated849,907857,050917,646851,9343,476,537






Trade and other receivables




As previously reported3,002,2543,334,3874,427,7173,882,3233,882,323
Adjustment(163,554)(260,160)(393,625)(521,666)(521,666)
Restated2,838,7003,074,2274,034,0923,360,6573,360,657






Corporation tax




As previously reported(131,854)(89,718)(155,433)(164,424)(164,424)
Adjustment17,36717,36717,36763,35463,354
Restated(114,487)(72,351)(138,066)(101,070)(101,070)






Net Assets




As previously reported22,227,77522,183,19221,785,54725,573,07725,573,077
Adjustment(146,187)(242,793)(376,258)(458,312)(458,312)
Restated22,081,58821,940,39921,409,289(458,312)25,114,765






2024 Adjustment Euro





Q12024Q22024Q32024

Adjusted EBITDA




As previously reported1,055,117896,916906,495

Adjustment40,21540,21540,215

Restated1,095,332937,131946,710

Importantly, these adjustments do not impact the company’s compliance with banking covenants related to its loan provider Santander Plc and have no impact on cash flow in any reporting period.

Physitrack Plc remains confident in its financial stability and operational integrity. While this adjustment highlights past issues, the corrective actions and strengthened controls position the company for a more robust and transparent financial reporting process.